Expertise in
5
conditions

Todd P. Mcmullen

Edmonton, AB, CA 
Clinical Trials:Currently Recruiting for 2 Trials
Expertise in
5
conditions
Edmonton, AB, CA 
OverviewLocationsClinical Research

Overview

Todd Mcmullen practices in Edmonton, Canada. Mr. Mcmullen is highly rated in 5 conditions, according to our data. His top areas of expertise are Mediastinal Tumor, Thyroid Cancer, Papillary Thyroid Cancer, Heart Tumor, and Thyroidectomy.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Edmonton, AB T6G1Z2, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
An Open-label Phase II Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Patients With Somatostatin Receptor Positive Tumours
Enrollment Status: Recruiting
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drug: [177]Lu-DOTA-TATE
Study Phase: Phase 2
A Phase I/II Study of Gallium-68 HA-DOTATATE ([68]Ga-HA-DOTATATE) in Patients With Known or Suspected Somatostatin Receptor Positive Tumours
A Phase I/II Study of Gallium-68 HA-DOTATATE ([68]Ga-HA-DOTATATE) in Patients With Known or Suspected Somatostatin Receptor Positive Tumours
Enrollment Status: Recruiting
Publish Date: May 14, 2025
Intervention Type: Drug
Study Drug: [68]Ga-HA-DOTATATE
Study Phase: Phase 1/Phase 2
A Pivotal Phase III Study of Cyclotron-produced Tc-99m Pertechnetate (CTC) Compared to Generator-produced Tc-99m Pertechnetate (G-PERT) in Subjects With Thyroid Disorders
A Pivotal Phase III Study of Cyclotron-produced Tc-99m Pertechnetate (CTC) Compared to Generator-produced Tc-99m Pertechnetate (G-PERT) in Subjects With Thyroid Disorders
Enrollment Status: Completed
Publish Date: April 11, 2022
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

46 Total Publications

First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α.
First-Generation Radiolabeled Cyclic Peptides for Molecular Imaging of Platelet-Derived Growth Factor Receptor α.
Journal: Molecular pharmaceutics
Published: August 17, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mcmullen's expertise for a condition
ConditionClose
      View All 9 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile